purinostat

Purinostat is a highly selective and active histone deacetylase (HDAC) inhibitor that specifically targets HDAC classes I and IIb. It demonstrates potent antineoplastic activities by selectively inhibiting the catalytic activity of class I HDACs (including HDAC1, 2, 3, and 8) and class IIb HDACs (including HDAC6 and 10). This inhibition results in an accumulation of highly acetylated chromatin histones, inducing chromatin remodeling and altering gene expression patterns. Consequently, purinostat inhibits tumor oncogene transcription while selectively promoting tumor suppressor gene transcription, which inhibits tumor cell division and induces tumor cell apoptosis. The compound has shown excellent activity against hematological malignancies, particularly in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).

Other names

Purinostat Mesylate